Bridgewater, NJ, United States of America

Sachin Maniar


Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Sachin Maniar

Introduction

Sachin Maniar, a notable inventor based in Bridgewater, NJ, has made significant contributions to the field of biochemistry and pharmaceuticals. His innovative work has led to the development of a patent that addresses critical medical conditions. With a focused expertise in glycosyltransferase inhibitors, Sachin showcases how targeted research can lead to potential treatments for serious diseases.

Latest Patents

Sachin holds a patent for "UDP glycosyltransferase inhibitors and methods of use." This patent details a compound of Formula (I) along with its pharmaceutically acceptable salts. The patent further describes various compositions using these compounds and their applications in treating diseases such as Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD). This advancement opens doors to new therapeutic options for conditions that have been challenging to manage.

Career Highlights

Currently, Sachin is associated with Genzyme Corporation, a company renowned for its innovative approaches in biotechnology and rare disease treatments. His work is a testament to the impact that focused research and development can have on patient care and treatment outcomes. The only patent for which he is credited emphasizes the importance of his contributions to the workplace and the larger medical community.

Collaborations

Throughout his career, Sachin has collaborated with esteemed colleagues, including Sungtaek Lim and Robert H Barker, Jr. These partnerships highlight the collaborative spirit of invention, exemplifying how collective expertise can lead to groundbreaking solutions in the biopharmaceutical industry.

Conclusion

Sachin Maniar's journey as an inventor underscores the pivotal role that innovation plays in advancing medical science. His work on UDP glycosyltransferase inhibitors not only showcases his talent but also emphasizes the importance of dedicated research in finding new treatments for rare diseases. As he continues to work at Genzyme Corporation, his contributions will likely pave the way for further advancements in the pharmaceutical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…